Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today presented a poster on Part 1, the open-label portion, of the study of SLS-002 at the IASRAFSP International Summit on Suicide Research Virtual Conference. The poster titled A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 .